Coenzyme Q10 therapy in lithotripsy in patients with renal lithiasis

Completed

• Conditions: Renal lithiasis; Urological and Genital Diseases; Calculus of kidney and ureter

• Registration Number: ISRCTN05823740
• Lead Sponsor: Association of Urology Research and Development (Asociacion de Urologia y Desarrollo de la Investigacion) (Spain)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-03-19
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

1. Adult patients aged 25 to 65 years (either sex) with urinary tract lithiasis
2. Candidates to applying lithotripsy
3. Lithiasis located in the renal pelvis and/or calyx

Exclusion Criteria

1. Patients undergoing lithotripsy at the time of initiating the study
2. Patients with previously diagnosed renal lithotripsy
3. Patients treated with calcium channel blockers
4. Complications of lithotripsy that determine the need for further intervention in the study period
5. Taking antiplatelet 3 days before extracorporeal shock-wave lithotripsy (ESWL) session
6. Controlled clotting disorders
7. Complete distal obstruction to the calculation to be treated
8. Unrecovery kidney
9. Allergy to the components of medications
10. Inability to understand or psychosocial misadjustment
11. Refusal to sign informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of glomerular filtration rate (MDRD), measured in June 2010 and September 2010

Secondary Outcome Measures

Name	Time	Method
Measured in June 2010 and September 2010:<br>1. Biochemical markers of oxidative stress: <br>1.1. MDA<br>1.2. Glutation<br>1.3. SOD<br>1.4. Catalase<br>